tiprankstipranks
Pacira Pharmaceuticals Announces Board Changes and Shareholder Approvals
Company Announcements

Pacira Pharmaceuticals Announces Board Changes and Shareholder Approvals

Pick the best stocks and maximize your portfolio:

An announcement from Pacira Pharmaceuticals (PCRX) is now available.

Gary Pace announced his plan to retire from the Board of Directors of Pacira BioSciences, Inc., effective June 30, 2024, with no disagreements cited. He will enter into a consulting agreement amendment for a year starting July 1, 2024. Additionally, the 2024 Annual Meeting saw the election of four directors, the ratification of KPMG LLP as the independent auditor, and approval of executive compensation, with a majority of stockholders voting in favor of these proposals.

For an in-depth examination of PCRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyDOMA Perpetual Capital to nominate four candidates to Pacira’s board
TheFlyPacira reports inducement grants under Nasdaq listing rule
TheFlyPacira awarded new U.S. patent covering EXPAREL composition
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App